


Date	September 5, 2025 (Friday)	
Location	Registration (13:00-16:40)	Room 2
14:00-15:40		Postgraduate Course (I)
15:40-16:00		Coffee Break
16:00-17:40		Postgraduate Course (II)
18:30-20:30		Faculty Dinner



Date	September 6, 2025 (Saturday)			
Location	Registration	Room 1	Room 2	Room 3
09:00 10:40		[Session 1] Disease Burden of Chronic Viral Hepatitis and MASLD and Liver Cancer in Asia-Pacific Area	[Session 2] Liver Cancer Prevention	
10:40 11:00		Coffee Break		
11:00 11:30		Opening Ceremony		
11:30 12:00		[Keynote Lecture] <i>Unmet Needs for HCC Management-----Specific target therapy, biomarkers and chemoprevention</i>  Pei-Jer Chen		
12:00 13:00		Luncheon Symposium [BMS]	Luncheon Symposium	Luncheon Symposium [GSK]
13:20 15:00		[Session 3] Pathogenesis and Tumor Microenvironment of Liver Cancer	[Session 4] Surveillance of Liver Cancer in Asia-Pacific Area	
15:00 15:20		Coffee Break		
15:20 17:00		[Session 5] Molecular Classification and Management of HCC	[Session 6] Locoregional Treatment for Liver Cancer	
17:00 18:00			Evening Symposium [Roche]	Evening Symposium [Eisai/MSD]
18:30 20:30	Gala Dinner			



Date	September 7, 2025 (Sunday)		
Location	Registration	Room 1	Room 2
08:30-09:30		Oral Presentation	YIA Presentation
09:30-11:10		[Session 7] Surgery for Liver Cancer (Borderline Resectable) - Downstaging for Surgical Resection or Liver Transplantation	[Session 8] Systemic Treatment for Liver Cancer
11:10–11:30		Coffee Break	
11:30-12:00		[Chairman Lecture] <i>Toward precision immunotherapy for hepatocellular carcinoma</i> Yi-Hsiang Huang	
12:00-13:00		Luncheon Symposium [Roche]	Luncheon Symposium [AstraZeneca]
13:20-15:00		[Session 9] Radiotherapy for Liver Cancer	[Session 10] Multidisciplinary Approach for Liver Cancer
15:00-15:20	Registration	Coffee Break	
15:20-17:00		[Session 11] Unmet Needs and Future Prospects	[Session 12] Hepatobiliary Cancer Outside of HCC: New Progress
17:00-17:30		Closing Ceremony	



## September 5, 2025 (Friday)

Postgraduate course (I)				Room 2
Moderators: Pei-Jer Chen (Taipei)				
13:55-14:00		Opening		
14:00-14:25	PC 1-1	Precision surveillance of HCC	Chao-Hung Hung	Kaohsiung
14:25-14:50	PC 1-2	Interplay between MASLD and viral hepatitis for hepatic carcinogenesis	Tai-Chung Tseng	Taipei
14:50-15:15	PC 1-3	Molecular-based biomarkers in HCC diagnosis and treatment	Sen-Yung Hsieh	Taoyuan
15:15-15:40	PC 1-4	Application of artificial intelligence in HCC and biliary tract cancer research	Tung-Hung Su	Taipei
15:40-16:00		Coffee Break		
Postgraduate course (II)				Room 2
Moderators: Chun-Jen Liu (Taipei)				
16:00-16:25	PC 2-1	Treatment strategy for intermediate-stage HCC: A surgeon's perspective	Etsuro Hatano	Kyoto
16:25-16:50	PC 2-2	Treatment strategy for intermediate-stage HCC: A medical oncologist's perspective	Changhoon Yoo	Seoul
16:50-17:15	PC 2-3	Immune booster locoregional treatment for HCC	Chien-Wei Su	Taipei
17:15-17:40	PC 2-4	New advances in the treatment of cholangiocarcinoma	Masafumi Ikeda	Tokyo





## September 6, 2025 (Saturday)

### Session 1: Disease Burden of Chronic Viral Hepatitis and MASLD and Liver Cancer in Asia-Pacific Area Room 1

**Moderators:** Mei-Hsuan Lee (Taipei) / Junko Tanaka (Hiroshima)

09:00-09:20	S1-1	<b>Chronic hepatitis B and C in the Asia-Pacific: Current burden and future trends</b>	Junko Tanaka	Hiroshima
09:20-09:40	S1-2	<b>Metabolic dysfunction-associated steatotic liver disease (MASLD) in the Asia-Pacific: Rising prevalence, risk factors, and implications for liver cancer</b>	Jee-Fu Huang	Kaohsiung
09:40-10:00	S1-3	<b>Primary prevention of chronic hepatitis B virus infection and its impact on liver cancer control in the younger generation</b>	Huey-Ling Chen	Taipei
10:00-10:20	S1-4	<b>Unraveling the liver cancer burden: Primary prevention strategies and long-term management in the Asia-Pacific</b>	Chien-Hung Chen	Taipei
10:20-10:40		<b>Discussion</b>		

### Session 2: Liver Cancer Prevention Room 2

**Moderators:** Chien-Wei Su (Taipei) / Daniel Qingyao Huang (Singapore)

09:00-09:20	S2-1	<b>Secondary and tertiary prevention of liver cancer in chronic hepatitis B patients</b>	Wen-Juei Jeng	Taoyuan
09:20-09:40	S2-2	<b>Risk and molecular mechanisms of liver cancer: occurrence and recurrence after hepatitis C virus eradication</b>	Ming-Lung Yu	Kaohsiung
09:40-10:00	S2-3	<b>Risk stratification and preventive approaches for liver cancer recurrence in MAFLD</b>	Daniel Qingyao Huang	Singapore
10:00-10:20	S2-4	<b>Prevention strategies for liver cancer in alcohol-related liver disease</b>	Han-Chieh Lin	Taipei
10:20-10:40		<b>Discussion</b>		



## September 6, 2025 (Saturday)

### Keynote Lecture Room 1

**Moderator: Yi-Hsiang Huang (Taipei)**

11:30-12:00	KL	<b>Unmet Needs for HCC Management----- Specific target therapy, biomarkers and chemoprevention</b>	<b>Pei-Jer Chen</b>	<b>Taipei</b>
-------------	----	--	---------------------	---------------

### Session 3: Pathogenesis and Tumor Microenvironment of Liver Cancer Room 1


**Moderators: Shiou-Hwei Yeh (Taipei) / Sze Lok Alfred Cheng (Hong Kong)**

13:20-13:45	S3-1	<b>Single-cell system for mapping the immune microenvironment in tumor development</b>	<b>Shih-Yu Chen</b>	<b>Taipei</b>
13:45-14:10	S3-2	<b>Update on HBV integration in HCC pathogenesis</b>	<b>Shiou-Hwei Yeh</b>	<b>Taipei</b>
14:10-14:35	S3-3	<b>Augment the efficacy of HCC immunotherapy by targeting the tumor immune microenvironment</b>	<b>Sze Lok Alfred Cheng</b>	<b>Hong Kong</b>
14:35-15:00	S3-4	<b>Liver organoids in mechanistic and therapeutic studies of HBV infection and hepatocarcinogenesis</b>	<b>Toshiro Sato</b>	<b>Tokyo</b>

### Session 4: Surveillance of Liver Cancer in Asia-Pacific Area Room 2

**Moderators: Chai-Yen Dai (Kaohsiung) / Jeong Hyun Lee (Seoul)**

13:20-13:45	S4-1	<b>Novel biomarkers for HCC surveillance &amp; circulating tumor cells/cell-free DNA for the detection of HCC</b>	<b>Takahiro Yamasaki</b>	<b>Yamaguchi</b>
13:45-14:10	S4-2	<b>Abbreviated MRI for detection of hepatic malignancies</b>	<b>Jeong Hyun Lee</b>	<b>Seoul</b>
14:10-14:35	S4-3	<b>Policy for surveillance of liver cancer in Asia-Pacific regions</b>	<b>Chun-Jen Liu</b>	<b>Taipei</b>
14:35-15:00		<b>Discussion</b>		



## September 6, 2025 (Saturday)

Session 5: Molecular Classification and Management of HCC				Room 1
Moderators: Chiun Hsu (Taipei) / Takahiro Kodama (Osaka)				
15:20-15:40	S5-1	Etiology and pathogenesis perspective	Yung-Yeh Su	Miaoli
15:40-16:00	S5-2	Drug development perspective	Takahiro Kodama	Osaka
16:00-16:20	S5-3	Immunology perspective	Ying-Chun Shen	Taipei
16:20-16:40	S5-4	Genomic and immunological approach for the management of HCC	Carmen C.L. Wong	Hong Kong
16:40-17:00		Discussion		

Session 6: Locoregional Treatment for Liver Cancer				Room 2
Moderators: Chia-Chi Wang (Taipei) / Shuichiro Shiina (Tokyo)				
15:20-15:45	S6-1	Comparison and selection of microwave ablation and radiofrequency ablation in the treatment of liver cancer	Shuichiro Shiina	Tokyo
15:45-16:10	S6-2	High-intensity ultrasound and histotripsy for tumor ablation	Chih-Horng Wu	Taipei
16:10-16:35	S6-3	Application of artificial intelligence in liver cancer ablation	I-Cheng Lee	Taipei
16:35-17:00		Discussion		



September 7, 2025 (Sunday)

Oral Presentation				Room 1
<b>Moderators:</b>				
08:30-08:42	O1-1	LG2m and AFP, when combined with PAGE-B, are highly effective in the risk-stratification of CHB patients for HCC	Chung-Feng Huang	Kaohsiung
08:42-08:54	O1-2	Increasing Alcohol Consumption is Associated with Significantly Increased Risks of Hepatocellular Carcinoma in Adults with Non-Cirrhotic MASLD or Met-ALD	Robert Wong	Stanford
08:54-09:06	O1-3	Enhanced risk stratification for liver-related events in post-HCV cure patients: incorporating von Willebrand factor-based predictor	Sheng-Hung Chen	Taichung
09:06-09:18	O1-4	A Seven-Year Review of Ultrasound-Guided Ablative Therapies for Colorectal Liver Metastases: Outcomes and Influencing Factors from a Single Center (2018-2024)	Ting-Yu Lin	Taipei
09:18-09:30	O1-5	Direct-acting antiviral improves liver function preservation and overall survival in patients with unresectable hepatocellular carcinoma	Shou Wu Lee	Taichung





September 7, 2025 (Sunday)

YIA Presentation				Room 2
Moderators:				
08:30-08:42	Y1-1	Globo H Ceramide Contributes to Gemcitabine Resistance and Worsens the Prognosis for Patients with Advanced Gallbladder Cancer via A2AR/cAMP/PKA Pathway	Tsai-Hsien Hung	Taoyuan
08:42-08:54	Y1-2	Synergistic effect of locoregional therapy in patients with unresectable hepatocellular carcinoma receiving immunotherapy	Wei-Fan Hsu	Taichung
08:54-09:06	Y1-3	Artificial Intelligence-assisted Prognostic Model and Risk Stratification for Patients with Cholangiocarcinoma	Chun-Ting Ho	Taipei
09:06-09:18	Y1-4	Impact of Gut Microbiome and Its Metabolites on the Recurrence of Hepatocellular Carcinoma Following Curative Resection	Mikee Elaine Wee	Manila
09:18-09:30	Y1-5	Positivity of High-Sensitivity HBSAG Test, Not Previous HBV Infection, Indicates Poor Prognosis in Patients with Non-HBV-Related HCC	Naohiro Yasuura	Hokkaido



## September 7, 2025 (Sunday)

### Session 7: Surgery for Liver Cancer (Borderline Resectable) - Downstaging for Surgical Resection or Liver Transplantation

Room 1

**Moderators: Wei-Chen Lee (Taoyuan) / Etsuro Hatano (Kyoto)**

09:30-09:55	S7-1	<b>Downstaging of intermediate stage HCC for liver transplantation</b>	<b>Wei-Chen Lee</b>	<b>Taoyuan</b>
09:55-10:20	S7-2	<b>Downstaging of advance stage HCC for liver transplantation or liver resection</b>	<b>Chih-Hsien Cheng</b>	<b>Taoyuan</b>
10:20-10:45	S7-3	<b>Liver transplantation for cholangiocarcinoma</b>	<b>Etsuro Hatano</b>	<b>Kyoto</b>
10:45-11:10		<b>Discussion</b>		

### Session 8: Systemic Treatment for Liver Cancer

Room 2

**Moderators: Teng-Yu Lee (Taichung) / Stephen L Chan (Hong Kong)**

09:30-09:55	S8-1	<b>The decision-making process for HCC systemic treatments in clinical practice</b>	<b>Stephen L Chan</b>	<b>Hong Kong</b>
09:55-10:20	S8-2	<b>Predictors of prognosis to systemic treatments in HCC</b>	<b>Changhoon Yoo</b>	<b>Seoul</b>
10:20-10:45	S8-3	<b>Perspective on systemic treatments for HCC</b>	<b>Ann-Lii Cheng</b>	<b>Taipei</b>
10:45-11:10		<b>Discussion</b>		

### Chairman Lecture

Room 1

**Moderator: Masao Omata (Tokyo)**

11:30-12:00	CL	<b>Toward precision immunotherapy for hepatocellular carcinoma</b>	<b>Yi-Hsiang Huang</b>	<b>Taipei</b>
-------------	----	--	------------------------	---------------



## September 7, 2025 (Sunday)

Session 9: Radiotherapy for Liver Cancer				Room 1
Moderators: Keng-Li Lan (Taipei) / Tatsuya Ohno (Gunma)				
13:20-13:45	S9-1	Heavy Ion therapy	Tatsuya Ohno	Gunma
13:45-14:10	S9-2	Proton Therapy for advanced HCC	Bing-Shen Huang	Taoyuan
14:10-14:35	S9-3	Y90 therapy	Yu-Fan Cheng	Kaohsiung
14:35-15:00		Discussion		

Session 10: Multidisciplinary Approach for Liver Cancer				Room 2
Moderators: Jia-Horng Kao (Taipei) / Masafumi Ikeda (Tokyo)				
13:20-13:45	S10-1	Multi-disciplinary cancer care: concept, execution, and the impact on management of hepatocellular carcinoma	Chiun Hsu	Taipei
13:45-14:10	S10-2	Multidisciplinary approach for intermediate stage HCC with high tumor burden	Wei Teng	Taoyuan
14:10-14:35	S10-3	Multidisciplinary approach for advanced HCC with main portal vein thrombosis	Masafumi Ikeda	Tokyo
14:35-15:00		Discussion		



## September 7, 2025 (Sunday)

Session 11: Unmet Needs and Future Prospects				Room 1
Moderators: Pin-Nan Cheng (Tainan) / Julien Calderaro (Créteil)				
15:20-15:45	S11-1	HCC control unmet needs and future prospects	Hsiu-Hsi Chen	Taipei
15:45-16:10	S11-2	Artificial intelligence in incorporating multidiscipline approaches in management of hepatocellular carcinoma: current evidence and clinical application	Julien Calderaro	Créteil
16:10-16:40		Discussion		

Session 12: Hepatobiliary Cancer Outside of HCC: New progress				Room 2
Moderators: Ming-Huang Chen (Taipei) / Do-Youn Oh (Seoul)				
15:20-15:45	S12-1	Understanding the tumor microenvironment in cholangiocarcinoma: implication for immunotherapy development	Ming-Huang Chen	Taipei
15:45-16:10	S12-2	Current status of biliary tract cancer	Li-Tzong Chen	Kaohsiung
16:10-16:35	S12-3	Future status of biliary tract cancer	Do-Youn Oh	Seoul
16:35-17:00		Discussion		

